Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.
about
Generation of high-affinity DNA aptamers using an expanded genetic alphabetBeyond DNA origami: the unfolding prospects of nucleic acid nanotechnologyEffect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori.A regular thymine tetrad and a peculiar supramolecular assembly in the first crystal structure of an all-LNA G-quadruplexActivating frataxin expression by repeat-targeted nucleic acidsMapping photothermally induced gene expression in living cells and tissues by nanorod-locked nucleic acid complexesNotch1-Dll4 signalling and mechanical force regulate leader cell formation during collective cell migration.Surprising base pairing and structural properties of 2'-trifluoromethylthio-modified ribonucleic acids.Dissecting the chemical interactions and substrate structural signatures governing RNA polymerase II trigger loop closure by synthetic nucleic acid analogues.Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs.Synthetic genetic polymers capable of heredity and evolution.Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia modelHigh-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.Synthesis and antiviral properties of spirocyclic [1,2,3]-triazolooxazine nucleosides.Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cellsNucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.GC-elements controlling HRAS transcription form i-motif structures unfolded by heterogeneous ribonucleoprotein particle A1The delivery of therapeutic oligonucleotidesSplice-switching antisense oligonucleotides as therapeutic drugsAptamers as theranostic agents: modifications, serum stability and functionalisationAllele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.Bacteriophage based probes for pathogen detection.Current progress on aptamer-targeted oligonucleotide therapeutics.Expanding the Scope of 2'-SCF3 Modified RNA.Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.Mismatch discrimination in fluorescent in situ hybridization using different types of nucleic acids.Endless: a purine-binding RNA motif that can be expressed in cells.Design, synthesis and properties of artificial nucleic acids from (R)-4-amino-butane-1,3-diol.Tuning molecular interactions in lipid-oligonucleotides assemblies via locked nucleic acid (LNA)-based lipids.Polyfluorinated groups in medicinal chemistry.Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma.The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.Modular Assembly of Cell-targeting Devices Based on an Uncommon G-quadruplex Aptamer.Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.Detection of mRNA in living cells by double-stranded locked nucleic acid probes.Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.A chemical perspective on transcriptional fidelity: dominant contributions of sugar integrity revealed by unlocked nucleic acidsPhotoinduced reductive electron transfer in LNA:DNA hybrids: a compromise between conformation and base stacking.Design and synthesis of LNA-based mercaptoacetamido-linked nucleoside dimers.Aptamers as the Agent in Decontamination Assays (Apta-Decontamination Assays): From the Environment to the Potential Application In Vivo.
P2860
Q22122129-5BEAF4E6-6083-4F2B-92DF-BC097D45B2EDQ26822686-81FA2A95-D0DA-4DCD-9FDE-465F0DCFD6FAQ27317349-F609A452-0121-4B6B-90D1-C58529F04A49Q27689082-9A671DDD-3690-4B6A-9E29-6A6254006373Q28272901-F3F77DF9-7CB3-4400-A208-52D5A9CDE698Q30577291-38C72AF2-7B42-41F5-A17B-60522BF848E9Q30634120-59F87B7E-0D1A-4052-B3AB-33CA356C2FFAQ30808960-04E3295B-4A5B-4EBB-B85E-69FCAEB4342AQ33635651-2105438B-C551-4345-87F1-D3A5A00FB957Q33939348-CB4A06DF-D40D-4A3A-88C0-F126EEEB4EEAQ34031569-F9D85912-C7B2-407B-8353-1DB9626C8A05Q34117470-1344D0E1-2EDE-4AEE-86D7-B7FFA1434868Q35131115-78EB54F2-C6C0-4CD0-8A26-EE13DAB3377FQ35216846-6D00B402-CDDB-4EFB-A3DF-225660078D1FQ36117908-606448F1-DB90-4424-B5DF-5362BE9238C1Q36367297-4202E299-F40D-4B5D-A6BA-DBCB68E66D2DQ36379638-855FD784-0F4B-409E-8D6B-0FEFC65D14F5Q37210936-C4CF97B5-B1FB-43DA-A8A5-C9542A9DAAB0Q37211004-9E71A32C-E242-42EF-B2AC-0391015EA607Q37383122-A0891E52-9BB3-473B-AE09-AA6FDAB850D2Q37483574-CDA5292F-9882-44E6-8405-1B26B17EE9EDQ38020842-9F95CA53-C0FF-4EF7-9948-ABC778E63862Q38168595-B7BF7766-CEE7-4F44-8ECD-417A94702769Q38298322-9FB47069-09A9-40D4-BBAF-DA514871EF45Q38299065-D0D75512-B65D-4A42-AE54-E32582D72F9FQ38299993-4DC7B8DB-CE90-4336-BC9F-C5EE05ED8528Q38305614-B73D87D3-D1DE-4038-B0C6-487BBF59F3ABQ38308740-AD119948-6090-48DD-997E-E892F92A0D95Q38312341-8ADCC58E-5875-4A86-85FB-D6EC55E5CB61Q38421820-3D166ED6-C57B-491A-89E6-B4F1316C2810Q38928155-238D70FF-D887-4877-A8DD-EE50C0A8B8E0Q38934039-43EDD900-12C5-4071-A367-82AAEA8A9C1BQ38968703-CABC7CCF-667B-4D57-AAC5-ACB39602AB65Q39106578-AB4369BD-72A3-4482-B503-F973858D4A0DQ39138791-2CF541E0-6CA4-4E4E-98EF-0ED3EB4FC408Q41573492-96354B64-C31F-4BCC-81B4-3DB3D4EC9554Q42031134-2CF93CCE-8520-40B4-B45F-21CE00D8BDE7Q44137528-DABD13C6-FB2D-467F-B746-339E41030AC6Q44357634-D73FDC32-4CCC-45E1-95C0-F03D964FD4FDQ47150038-1CFCC233-5F45-4DCD-8E19-173718212073
P2860
Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Locked vs. unlocked nucleic ac ...... ards common therapeutic goals.
@en
Locked vs. unlocked nucleic acids
@nl
type
label
Locked vs. unlocked nucleic ac ...... ards common therapeutic goals.
@en
Locked vs. unlocked nucleic acids
@nl
prefLabel
Locked vs. unlocked nucleic ac ...... ards common therapeutic goals.
@en
Locked vs. unlocked nucleic acids
@nl
P2860
P356
P1476
Locked vs. unlocked nucleic ac ...... ards common therapeutic goals.
@en
P2860
P304
P356
10.1039/C1CS15048K
P577
2011-05-10T00:00:00Z